Compare · BSX vs IRTC
BSX vs IRTC
Side-by-side comparison of Boston Scientific Corporation (BSX) and iRhythm Holdings Inc. (IRTC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and IRTC operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $72.26B, about 17.8x IRTC ($4.06B).
- Over the past year, BSX is down 53.1% and IRTC is down 26.8% - IRTC leads by 26.4 points.
- IRTC has been more active in the news (13 items in the past 4 weeks vs 10 for BSX).
- Both have 25 recent analyst ratings on file.
- Company
- Boston Scientific Corporation
- iRhythm Holdings Inc.
- Price
- $49.86+1.73%
- $123.10-1.65%
- Market cap
- $72.26B
- $4.06B
- 1M return
- +9.58%
- +9.69%
- 1Y return
- -53.13%
- -26.76%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2016
- News (4w)
- 10
- 13
- Recent ratings
- 25
- 25
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
iRhythm Holdings Inc.
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. iRhythm Technologies, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Latest BSX
- SEC Form 4 filed by SVP, Global Controller and CAO Woodworth Emily
- SEC Form 4 filed by EVP and CFO Monson Jonathan
- Boston Scientific announces participation in Wells Fargo 21st Annual Healthcare Conference and conference call discussing third quarter 2026 results
- Director Habiger David C bought $99,937 worth of shares (2,100 units at $47.59), increasing direct ownership by 14% to 17,160 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Boston Scientific Corporation
- Director Habiger David C bought $56,887 worth of shares (1,182 units at $48.13), increasing direct ownership by 9% to 15,060 units (SEC Form 4)
- Chairman, President & CEO Mahoney Michael F bought $9,001,408 worth of shares (186,240 units at $48.33), increasing direct ownership by 13% to 1,590,024 units (SEC Form 4)
- SEC Form 4 filed by EVP & Group Pres, Cardiology Fitzgerald Joseph Michael
- Director Ludwig Edward J bought $227,400 worth of shares (5,000 units at $45.48), increasing direct ownership by 20% to 30,359 units (SEC Form 4)
- SEC Form 10-Q filed by Boston Scientific Corporation
Latest IRTC
- iRhythm Holdings Inc. filed SEC Form 8-K: Leadership Update
- President and CEO Blackford Quentin S. was granted 48,534 shares and sold $3,348,012 worth of shares (26,859 units at $124.65), increasing direct ownership by 11% to 226,008 units (SEC Form 4) (for withholding tax)
- CBO and CLO Murphy Patrick Michael was granted 13,589 shares and sold $884,156 worth of shares (7,093 units at $124.65), increasing direct ownership by 10% to 69,699 units (SEC Form 4) to satisfy withholding tax
- EVP, Chief Risk Officer Shrishrimal Sumi was granted 9,706 shares and sold $669,641 worth of shares (5,372 units at $124.65), increasing direct ownership by 11% to 44,621 units (SEC Form 4) (withholding tax)
- CHIEF COMM & PRODUCT OFFICER Patterson Chad was granted 13,589 shares and sold $884,170 worth of shares (7,093 units at $124.65), increasing direct ownership by 12% to 62,125 units (SEC Form 4) (for withholding tax)
- CHIEF MED/SCI OFCR EVP ADVTECH Turakhia Minang sold $884,151 worth of shares (7,093 units at $124.65) and was granted 13,589 shares, increasing direct ownership by 12% to 60,116 units (SEC Form 4) to satisfy tax liability
- SEC Form 10-Q filed by iRhythm Holdings Inc.
- iRhythm Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- iRhythm Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- iRhythm to Acquire VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care